Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Silmitasertib - Senhwa Biosciences

Drug Profile

Silmitasertib - Senhwa Biosciences

Alternative Names: CX 4945

Latest Information Update: 13 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cylene Pharmaceuticals
  • Developer Cylene Pharmaceuticals; Penn State College of Medicine; Senhwa Biosciences; Stanford University School of Medicine
  • Class 3-ring heterocyclic compounds; Antineoplastics; Antivirals; Carboxylic acids; Naphthyridines; Small molecules
  • Mechanism of Action Casein kinase II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Biliary cancer; Cholangiocarcinoma; Medulloblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Community-acquired pneumonia; COVID 2019 infections
  • Phase I/II Cholangiocarcinoma; Medulloblastoma
  • Phase I Basal cell cancer
  • Preclinical Acute myeloid leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
  • No development reported Giant lymph node hyperplasia; Multiple myeloma; Solid tumours

Most Recent Events

  • 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Cholangiocarcinomapresented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 20 Mar 2024 Phase-II clinical trials in Community-acquired pneumonia (Combination therapy) in Taiwan (PO) (NCT06202521)
  • 08 Mar 2024 Pediatric Brain Tumor Consortium suspends phase I/II clinical trial in Medulloblastoma (Second-line therapy or greater, Recurrent, In adolescents, In adults, In children, In the elderly) in USA (PO) due to drug supply issues(NCT03904862)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top